Iovance Biotherapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell IOVA and other ETFs, options, and stocks.About IOVA
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors.
CEOFrederick G. Vogt
CEOFrederick G. Vogt
Employees557
Employees557
HeadquartersSan Carlos, California
HeadquartersSan Carlos, California
Founded2007
Founded2007
Employees557
Employees557
IOVA Key Statistics
Market cap3.81B
Market cap3.81B
Price-Earnings ratio-7.19
Price-Earnings ratio-7.19
Dividend yield—
Dividend yield—
Average volume3.83M
Average volume3.83M
High today$13.88
High today$13.88
Low today$12.87
Low today$12.87
Open price$13.46
Open price$13.46
Volume4.29M
Volume4.29M
52 Week high$18.33
52 Week high$18.33
52 Week low$3.21
52 Week low$3.21
IOVA News
Yahoo Finance 4d
Iovance Biotherapeutics to Present at Upcoming Conferences - Yahoo FinanceIovance Biotherapeutics, Inc. SAN CARLOS, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focu...
Yahoo Finance 5d
With 63% ownership of the shares, Iovance Biotherapeutics, Inc. is heavily dominated by institutional ... - Yahoo FinanceKey Insights Given the large stake in the stock by institutions, Iovance Biotherapeutics' stock price might be vulnerable to their trading decisions 51% of th...
Yahoo Finance 6d
Where Will Iovance Biotherapeutics Stock Be in 5 Years? - Yahoo FinanceThere's a lot of excitement around Iovance Biotherapeutics (NASDAQ: IOVA) as its shares are up over 40% year-to-date. Investors and analysts both see even more...
Analyst ratings
93%
of 14 ratingsBuy
92.9%
Hold
7.1%
Sell
0%